Roche to review pay for Genentech staff

Employees at Genentech, the US biotech company recently acquired by Roche, are set to receive a much higher proportion of their future remuneration in long-term stock options than their peers across the Swiss pharmaceutical group’s operations.

Severin Schwan, Roche’s chief executive, said that a review of pay at Genentech will be one of his top priorities next year, and stressed that new arrangements had to be “entrepreneurial”.